EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

Positive

AI Analysis

Summary

EpiVax announced AI-enhanced updates to its ISPRI™ platform, including an updated JanusMatrix™ model for assessing immunogenicity risk of biotherapeutics. This represents a routine technology enhancement to the company's proprietary in silico prediction platform.

Importance:3/10

Sentiment:

0.40

AIplatformimmunogenicitybiotherapeuticstechnology

Read the original article

Published by PR Newswire Biotech on September 2, 2026 3:04 PM

Read Original